Understanding Your CMML Diagnosis

Receiving a diagnosis of Chronic Myelomonocytic Leukemia (CMML) can feel overwhelming, especially because it is a rare condition that doesn’t fit neatly into a single category. You are likely dealing with a flood of new terms and a significant emotional weight. It is important to know that you are not alone; while CMML is rare—affecting roughly 0.3 to 0.6 out of every 100,000 people—there is a dedicated global community of researchers and clinicians focused on understanding and treating it ^[1][2].

CMML primarily affects older adults, with a median age at diagnosis between 73 and 75, and it is more commonly diagnosed in men ^[2][3]. Because it is a chronic condition that can be indolent in some people but rapidly progressive in others, your care team will focus on a long-term strategy tailored to your specific biological “fingerprint.”

A Unique “Overlap” Syndrome

CMML is classified as an MDS/MPN overlap syndrome. This means it acts like two different types of blood cancer at the same time:

• Myelodysplastic Syndrome (MDS) features: Your bone marrow struggles to produce healthy, functioning blood cells. This “ineffective” production often leads to low blood counts (cytopenias), such as anemia, which can cause fatigue ^[4][5].
• Myeloproliferative Neoplasm (MPN) features: Your marrow overproduces certain types of white blood cells. In CMML, this overproduction is focused on monocytes, a type of white blood cell that helps the body fight infections ^[4].

This overlap explains why some patients have low red blood cell counts while simultaneously having a very high total white blood cell count.

The Biological Mechanism: Why It Happens

CMML is caused by somatic mutations—genetic changes that happen in your blood cells over time rather than being inherited from your parents. These mutations occur in a “master” cell called a hematopoietic stem cell ^[6].

When these mutations occur, they give that cell a competitive advantage, allowing it to multiply more than healthy cells. This is known as clonal hematopoiesis. In CMML, this process is “skewed” toward the production of monocytes ^[4]. These abnormal cells can also release inflammatory signals, which may contribute to symptoms like night sweats or weight loss.

Key mutations often found in CMML include:

• TET2: Often an early mutation that starts the process by changing how DNA is regulated, although it is not invariably the founder mutation ^[4][6].
• SRSF2: A mutation that affects how cells process genetic instructions (RNA splicing) ^[7].
• ASXL1: A mutation often associated with more aggressive disease or a higher risk of the condition changing over time, though the exact risk depends on the specific variant and broader molecular context ^[5][8].

How CMML is Diagnosed

To confirm a diagnosis of CMML, doctors look for specific markers in your blood and bone marrow. Guidelines from the World Health Organization (WHO) and the International Consensus Classification (ICC) were updated in 2022 to help doctors diagnose the condition more accurately ^[9].

1. Monocyte Counts and Evidence of Disease

The hallmark of CMML is a persistent increase in monocytes (monocytosis). However, having high monocytes for three months is necessary but not sufficient for a diagnosis. The updated criteria state that:

• Your absolute monocyte count must be at least 0.5 x 10⁹/L ^[9][10].
• Monocytes must make up at least 10% of your total white blood cell count ^[9].
• This elevation must typically be present for at least 3 months to rule out temporary causes like a viral infection ^[9].
• The doctor must also find dysplasia (abnormal-looking cells in the bone marrow) or evidence of a clonal abnormality (a genetic mutation driving the growth), and rule out other diseases ^[9].

2. Blast Percentages

Doctors also measure blasts, which are immature, “baby” blood cells. In CMML, the blast count must be less than 20%. If it rises to 20% or higher, the condition is usually classified as Acute Myeloid Leukemia (AML) ^[11]. CMML is further divided into groups based on these percentages:

• CMML-1: Fewer than 5% blasts in the blood and fewer than 10% in the bone marrow ^[12].
• CMML-2: 5–19% blasts in the blood or 10–19% in the marrow ^[12].

3. Dysplastic vs. Proliferative Types

Your doctor may also categorize your CMML based on your total white blood cell (WBC) count:

• Dysplastic (MD-CMML): WBC count is less than 13 x 10⁹/L. This type often resembles MDS, with a focus on low blood counts ^[9].
• Proliferative (MP-CMML): WBC count is 13 x 10⁹/L or higher. This type is more “active,” often associated with an enlarged spleen (splenomegaly) or higher levels of inflammation ^[9][13].

Understanding which “type” and “group” you have helps your care team determine the most effective way to monitor and manage your health.